Allergizer, Not Pfizergan: How $16bn In Sales Could Be Worth $160bn
This article was originally published in Scrip
Executive Summary
If Pfizer can do for Allergan's products what Sanofi did for Genzyme's and Roche did for Intermune's then its new acquisition may actually pay off – by putting Pfizer ahead in a new pharma game, a game that Allergan knows better.